RG
ANIK icon

Rathbones Group’s Anika Therapeutics ANIK Stock Holding History

Rathbones Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,675
Closed -$254K – 306
2016
Q1 		$254K Sell
5,675
-1,000
-15% -$40.6K 0.02% 240
2015
Q4 		$252K Sell
6,675
-625
-9% -$23.9K 0.02% 247
2015
Q3 		$232K Hold
7,300
– – 0.02% 260
2015
Q2 		$241K Sell
7,300
-500
-6% -$17.8K 0.02% 268
2015
Q1 		$321K Buy
7,800
+1,500
+24% +$60.6K 0.02% 244
2014
Q4 		$257K Sell
6,300
-510
-7% -$19.9K 0.02% 263
2014
Q3 		$250K Buy
+6,810
New +$294K 0.02% 258

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Rathbones Group's ANIK Position: Q2 2016 in Review

Rathbones Group sold out of Anika Therapeutics (ANIK) in Q2 2016, closing a stake of 5,675 shares — an estimated $254K sold.

Rathbones Group first reported a position in ANIK in Q3 2014 and held it in 7 quarters. The position peaked at $321K in Q1 2015. 160 funds tracked by Wall St. Rank hold ANIK as of Q2 2016.

  • Rathbones Group reported no remaining Anika Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Rathbones Group sold 5,675 Anika Therapeutics shares in Q2 2016, an estimated $254K.
  • Rathbones Group first reported a position in Anika Therapeutics in Q3 2014 and held it in 7 quarters.
  • Rathbones Group's Anika Therapeutics position peaked at $321K in Q1 2015.
  • 160 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2016.

Based on Rathbones Group's 13F filing for Q2 2016, filed 3 Aug 2016.